Announcements Trials
Browse Landscape

Phase

Phase 3 12Phase 2 8Phase 1 4Phase 1/2 2Phase NA 1

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 2Sarcoma 1Lymphoid 1

Conditions

Breast Neoplasms 2Sarcoma 1Recurrence 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1

Interventions

Specimen Handling 51pembrolizumab 46Magnetic Resonance Spectroscopy 38Biopsy 37Cyclophosphamide 34fludarabine 29Cetuximab 20Cisplatin 19Carboplatin 19Radiotherapy 16Bevacizumab 16atezolizumab 15Radiation 15venetoclax 14Nivolumab 14Fluorouracil 14fludarabine phosphate 13Leucovorin 13Gemcitabine 13Temozolomide 11Pemetrexed 11Oxaliplatin 11Cytarabine 11Paclitaxel 10Irinotecan 10Ipilimumab 10130-nm albumin-bound paclitaxel 10Prednisone 9Immunoglobulin G 9Fulvestrant 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × palbociclib × 30 days × Clear all
NCT06570031 2026-06-05

ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

Ono Pharmaceutical Co., Ltd.

Phase 1 Completed
46 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT02159755 2026-05-27

Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
28 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT06113809 2026-05-22

Palbociclib and Pembrolizumab in Sarcoma

University of Iowa

Phase 1 Recruiting
8 enrolled
Sarcoma

Sarcoma

NCT03332797 2026-05-15

A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

Genentech, Inc.

Phase 1 Active not recruiting
181 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡